electroCore

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell electroCore and other ETFs, options, and stocks.

About ECOR

electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. It develops a platform bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. 

CEO
Daniel S. Goldberger
CEODaniel S. Goldberger
Employees
73
Employees73
Headquarters
Rockaway, New Jersey
HeadquartersRockaway, New Jersey
Founded
2005
Founded2005
Employees
73
Employees73

ECOR Key Statistics

Market cap
57.44M
Market cap57.44M
Price-Earnings ratio
-3.98
Price-Earnings ratio-3.98
Dividend yield
Dividend yield
Average volume
99.85K
Average volume99.85K
High today
$7.39
High today$7.39
Low today
$6.55
Low today$6.55
Open price
$6.74
Open price$6.74
Volume
156.75K
Volume156.75K
52 Week high
$19.49
52 Week high$19.49
52 Week low
$4.16
52 Week low$4.16

Stock Snapshot

The current electroCore(ECOR) stock price is $7.39, with a market capitalization of 57.44M. The stock trades at a price-to-earnings (P/E) ratio of -3.98.

On 2026-01-19, electroCore(ECOR) stock traded between a low of $6.55 and a high of $7.39. Shares are currently priced at $7.39, which is +12.9% above the low and 0.0% below the high.

electroCore(ECOR) shares are trading with a volume of 156.75K, against a daily average of 99.85K.

In the last year, electroCore(ECOR) shares hit a 52-week high of $19.49 and a 52-week low of $4.16.

In the last year, electroCore(ECOR) shares hit a 52-week high of $19.49 and a 52-week low of $4.16.

People also own

Based on the portfolios of people who own ECOR. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .